Jinwon Life Sciences Signs Plasmid DNA Supply Contract Worth 2.7 Million USD
Jinwon Life Sciences announced on the 30th that it has signed a plasmid DNA pharmaceutical supply contract worth 2.7 million dollars with a U.S. biotech company.
A company representative explained, "The name of the contracting party cannot be disclosed due to a confidentiality clause in the contract, and when converted to Korean won, the contract amount is approximately 3.8 billion won."
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Introduces New "Special Performance Bonus" for Semiconductors, Paid Entirely in Company Shares
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- Producer Price Index Hits Highest Growth in 28 Years... Consumer Price Pressure Mounts
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Park Young-geun, CEO of Jinwon Life Sciences, said, "Based on the differentiated large-scale, high-quality plasmid DNA production capabilities of our subsidiary VGXI, we have been expanding our sales force and conducting aggressive marketing, resulting in visible achievements leading to the signing of contract manufacturing agreements."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
